Startup using neuromodulation device to treat crohn's

[nogutsnoglory]

This is a very unique therapy that is currently being investigated by a start up. Never heard of anything like this being done yet. I am encouraged by the multiple angles researchers are taking to fight this disease.

http://mddionline.com/node/10641

 

[Igor_Passau]

Inflammation plays a significant role in acute and chronic diseases including rheumatoid arthritis (RA), inflammatory bowel disease (IBD), psoriasis, diabetes, heart disease, and multiple sclerosis.

SetPoint co-founder Kevin Tracey and his colleagues discovered and characterized the Inflammatory Reflex, which is a neurophysiological mechanism that regulates the body's immune system. The Inflammatory Reflex senses infection, tissue injury and inflammation and relays this information to the central nervous system, which then reflexively increases neural signaling peripherally through the vagus nerve and splenic nerve that extensively innervate the spleen and other visceral organs. The signal is transmitted to a novel population of T cells in the spleen, which in turn direct effector cells including monocytes and macrophages to reduce their production of the mediators that initiate and perpetuate inflammation.

Dr. Tracey published his findings in Nature in May 2000. Since then, the Inflammatory Reflex has been characterized by his group and others in more than 100 peer-reviewed papers in leading scientific journals, exploring the potential of activating the Inflammatory Reflex to alleviate inflammation. Dr. Tracey co-founded SetPoint Medical with Dr. Shaw Warren to leverage these discoveries in developing new therapies to treat chronic inflammatory diseases.
http://www.setpointmedical.com/inflammatory-reflex.php

 

[Igor_Passau]

First-in-Human Pilot Study Validates Neuromodulation Approach

SetPoint Medical announced positive results from the first-ever human study using an implanted neuromodulation device to treat rheumatoid arthritis at the American College of Rheumatology Annual Meeting in November 2012.

The results of this open-label pilot study confirm extensive preclinical studies and show efficacy with neuromodulation. The results are similar to those typically achieved in larger studies with drugs currently used to treat RA. At the primary end point, using the Disease Activity Score (DAS) and the American College of Rheumatology Response Rate (ACR), both standard RA efficacy measures for RA, two of the eight patients in the study achieved DAS remission, and six of the eight had a positive ACR 20 response.

http://www.setpointmedical.com/neuromodulation.php

 

[araceli]

I have been looking into neuromodulation for a while. I really want to give it a try for my son, and I will, I have heard a lot of good stories about it. I just need to save some money.